Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep
18
2017
Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment First Seven Subjects Receiving ProTmune Clear Phase 1 Safety Objectives of Engraftment and Survival at Day 28 Phase 1 Day 100 Acut... Read All »
Sep
14
2017
SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A. as Senior Vice President, Corporate Development. M... Read All »
Sep
01
2017
SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at three upcoming inve... Read All »
Aug
16
2017
SAN DIEGO, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,641 covering the use of pr... Read All »
Aug
14
2017
First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Con... Read All »
Aug
09
2017
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2017 We... Read All »
Aug
08
2017
Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate FDA Clears IND for FATE-NK100 in Ovarian Cancer SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company ded... Read All »
Aug
07
2017
SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, August ... Read All »
May
15
2017
ProTmune™ PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced Solid Tumors ... Read All »
May
10
2017
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's investiga... Read All »
May
08
2017
SAN DIEGO, May 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 15, ... Read All »
Apr
27
2017
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will host a Focus Session entitled "Off-the-Shelf Natural Killer Cell Cancer ... Read All »
Apr
20
2017
SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will present at the 5... Read All »
Mar
16
2017
First Subject Treated with ProTmune™ for GvHD Prevention IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML First-of-Kind Cancer Immunotherapy Derived from Engineered Pluripotent Cell Line to Begin Clinical Translation... Read All »
Mar
13
2017
SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational ne... Read All »
Page:
...
Next Last
 
= add release to Briefcase